Presentation By Catalent Expert At Upcoming Industry Summit
By 2020, patents protecting about $100 billion in annual sales of originator’s molecules will have expired, and biosimilars are expected to take 30% of this share. With competition dramatically increasing, and where the main objective for most is to reach market “first”, players are looking for ways to accelerate development of complex biosimilar molecules. Dr. Dagoneau’s presentation, on Thursday, Feb. 23, at 12:30 p.m., is entitled “Navigating Complex Biosimilars and New Biological Entities Development with Implications of Technology Integration to Bring Pipelines to Market Faster,” and will reflect on current biosimilar development trends, actual company business models, and how end-to-end integration of development, analytical and manufacturing activities can accelerate timelines.
Dr. Dagoneau has been involved in the design of biologics and biosimilar development programs at Catalent for the past five years. Prior to joining Catalent, she served as Head of Marketing and Sales at PX’Therapeutics for six years, and held additional commercial, marketing and research funding roles, both in France and in the United Kingdom, between 2001 and 2005. Dr. Dagoneau holds a doctorate in Organic Chemistry and a master’s in Technology & Business Management, both obtained from Grenoble Business School.
For more information on the Conference, visit: http://www.vonlanthengroup.com/en/events/3rd-annual-biosimilars-summit.html and to arrange a meeting with Dr. Dagoneau at the event, contact Richard Kerns at NEPR – richard@nepr.eu.
For more information on Catalent Biologics, visit www.catalentbiologics.com
ABOUT CATALENT
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and global clinical supply services. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit www.catalent.com